Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fernando Cabanillas

Showing results (81-90 of 86) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 86 results.
British Journal of Haematology|July 23, 2016
Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum β2-microglobulin level in patients with diffuse large b-cell lymphoma: a new prognostic modelYiming Chen, Sattva Neelapu, Lei Feng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2002
CD20 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin's disease: associations with presenting features and clinical outcomeGeorge Z Rassidakis, L Jeffrey Medeiros, Simonetta Viviani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2024
Efficacy and Safety of Denileukin Diftitox-Cxdl, an Improved Purity Formulation of Denileukin Diftitox, in Patients With Relapsed or Refractory Cutaneous T-Cell LymphomaFrancine M Foss, Youn H Kim, H Miles Prince, et al.
The Lancet. Oncology|June 9, 2012
Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trialMichael Wang, Luis Fayad, Nicolaus Wagner-Bartak, et al.
British Journal of Haematology|April 19, 2017
Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphomaPeter Martin, Zhengming Chen, Bruce D Cheson, et al.
European Journal of Haematology|December 6, 2019
Evaluation of the MD Anderson tumor score for diffuse large B-cell lymphoma in the rituximab eraAntonio Gutierrez, Leyre Bento, Antonio Diaz-Lopez, et al.
Pageof 9

Showing results (81-90 of 86) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 86 results.
British Journal of Haematology|July 23, 2016
Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum β2-microglobulin level in patients with diffuse large b-cell lymphoma: a new prognostic modelYiming Chen, Sattva Neelapu, Lei Feng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2002
CD20 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin's disease: associations with presenting features and clinical outcomeGeorge Z Rassidakis, L Jeffrey Medeiros, Simonetta Viviani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2024
Efficacy and Safety of Denileukin Diftitox-Cxdl, an Improved Purity Formulation of Denileukin Diftitox, in Patients With Relapsed or Refractory Cutaneous T-Cell LymphomaFrancine M Foss, Youn H Kim, H Miles Prince, et al.
The Lancet. Oncology|June 9, 2012
Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trialMichael Wang, Luis Fayad, Nicolaus Wagner-Bartak, et al.
British Journal of Haematology|April 19, 2017
Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphomaPeter Martin, Zhengming Chen, Bruce D Cheson, et al.
European Journal of Haematology|December 6, 2019
Evaluation of the MD Anderson tumor score for diffuse large B-cell lymphoma in the rituximab eraAntonio Gutierrez, Leyre Bento, Antonio Diaz-Lopez, et al.
Pageof 9